Pharvaris (NASDAQ:PHVS) Reaches New 52-Week Low – Here’s What Happened

Pharvaris (NASDAQ:PHVS)’s share price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $15.00 and last traded at $15.60, with a volume of 35777 shares traded. The stock had previously closed at $15.54.

Analysts Set New Price Targets

Separately, JMP Securities increased their price target on shares of Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a research note on Friday, January 31st.

Pharvaris Stock Performance

The company’s 50 day simple moving average is $17.99 and its 200-day simple moving average is $19.34. The firm has a market capitalization of $808.40 million, a PE ratio of -5.52 and a beta of -3.07.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Public Employees Retirement System of Ohio purchased a new position in shares of Pharvaris in the third quarter worth $57,000. JPMorgan Chase & Co. boosted its holdings in shares of Pharvaris by 1,125.3% in the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company’s stock valued at $59,000 after acquiring an additional 2,847 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Pharvaris during the 4th quarter worth about $64,000. Barclays PLC acquired a new position in Pharvaris in the 3rd quarter valued at $106,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Pharvaris in the fourth quarter valued at about $111,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.